Fair Value Calculator Fair Value Calculator
EN DE

Novozymes A/S (NSIS-B) Fair Value & Analysis

Basic Materials · DK · Market cap 201B DKK

NA Novozymes A/S NSIS-B · CO
Pricekr 423.60
Fair Valuekr 359.32
Upside-15.2%
Quality62/100
Watch Novozymes A/S for free, get notified when fair value or trend changes. Watch for free
Evidence: High Range kr 269.50 – kr 449.16 📤 Share as image

Fair value as of: Jul 18, 2026

From 26 valuation models · updated 4 days ago

Share price +7.5% over the past month.

Price vs Fair Value (12 months)

kr 445.80 kr 337.86 Fair Value kr 359.32 Jul 2025 Jul 2026

12‑month range kr 337.86 – kr 445.80 · fair‑value band kr 269.50 – kr 449.16 · the kr 423.60 price screens above the kr 359.32 fair value. As of Jul 18, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Novozymes A/S (NSIS-B) currently trades at kr 423.60, while our model-based Fair Value estimate is kr 359.32, implying the stock looks roughly 15.2% overvalued today. We read business quality at 62/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Novozymes A/S generated revenue of 4.2B DKK at a net margin of 14.2%. Revenue grew 3.9% year over year. It earns a return on equity of 5.4%. Net debt stands at 22.2B DKK. Fundamentals as of Jul 18, 2026

Our scenario range runs from kr 269.50 (bear case) to kr 449.16 (bull case); at kr 423.60, the current price sits within that range. The share trades about 12% below its 52-week high and 27% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -69% fair-value upside, at -15%, NSIS-B screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 4.2B DKK
Revenue growth (YoY) +3.9%
Net margin 14.2%
Return on equity 5.4%
Free cash flow 751M DKK FY2025
P/E ratio 44.9
More key figures
Operating margin 24.4%
EPS (TTM) kr 9.61
Dividend yield 0.2%
EPS growth (YoY) +7.5%
Net debt 22.2B DKK FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.

About the company

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Novozymes A/S reported revenue of kr 4.2B in FY2025 versus kr 15.0B in FY2021, a compound −27.4%/yr. Reported net income was kr 583M in FY2025, compounding −34.4%/yr from FY2021.

Revenue −27.4%/yr
FY21 kr 15.0B
FY22 kr 2.4B
FY23 kr 17.9B
FY24 kr 3.8B
FY25 kr 4.2B
Net income −34.4%/yr
FY21 kr 3.1B
FY22 kr 493M
FY23 kr 3.0B
FY24 kr 306M
FY25 kr 583M

Is NSIS-B fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Novozymes A/S Fair Value". https://www.fairvalue-calculator.com/stock/NSIS-B

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $509.16 $159.69 -69%
Nan Ya Plastics Corporation 1303 104.50 TWD 4.87 TWD -95%
Intercontinental Exchange, Inc I1CE34 R$367.00 R$311.38 -15%
Wanhua Chemical Group 600309 ¥74.30 ¥68.03 -8%
Asian Paints Limited ASIANPAINT ₹2,674 ₹739.38 -72%
PPG Industries, Inc PPG 1,988 MXN 1,169 MXN -41%
Solar Industries India Limited SOLARINDS ₹17,697 ₹2,793 -84%
Pidilite Industries Limited PIDILITIND ₹1,507 ₹393.58 -74%
PT Chandra Asri Pacific Tbk TPIA 1,955 IDR 2,350 IDR +20%
Linde India Limited LINDEINDIA ₹7,115 ₹757.93 -89%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Novozymes A/S (NSIS-B) undervalued?
As of Jul 18, 2026, our model estimates a fair value of kr 359.32 versus a price of kr 423.60, about −15% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NSIS-B?
Our model-based fair value for Novozymes A/S is kr 359.32 (as of Jul 18, 2026), built from audited fundamentals. The current price is kr 423.60.
What is the quality score of NSIS-B?
Novozymes A/S has a Quality Score of 62/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Novozymes A/S (NSIS-B)?
Novozymes A/S reported trailing-twelve-month revenue of about 4.2B DKK (latest available figure, as of Jul 18, 2026).
What is the net profit margin of NSIS-B?
The net profit margin of Novozymes A/S is about 14.2%, meaning it keeps roughly 14.2% of revenue as net income. Based on the latest reported figures.
Does Novozymes A/S pay a dividend?
Novozymes A/S currently shows a dividend yield of about 0.23% relative to its recent price (as of Jul 18, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Unlock the full Novozymes A/S analysis, and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.